CDK4 and Arthralgia: In our systematic review of phase III RCTs, arthralgias were reported in 13.2 to 68.7% of patients receiving AIs for early-stage breast cancer, while arthralgias induced by CDK4/6 inhibitors occurred in a much lower rate [20.5–41.2%].